Skip to main content
CRESCENT BIOPHARMA, INC. logo

CRESCENT BIOPHARMA, INC. — Investor Relations & Filings

Ticker · CBIO ISIN · US38000Q1022 US Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2020-04-09 Major Shareholding Noti…
Country US United States of America
Listing US CBIO

About CRESCENT BIOPHARMA, INC.

https://www.crescentbiopharma.com/

Crescent Biopharma, Inc. is a biopharmaceutical company dedicated to researching and developing the next wave of cancer therapies. The company's vision is to build a world-leading oncology organization by focusing on revolutionary shifts in the field to transform cancer treatment. Its strategy involves advancing a pipeline of therapies with multiple modalities, including precision-engineered small molecule therapeutics, designed to address cancer on various fronts. Crescent Biopharma aims to deliver a new standard of care for people living with cancer through its innovative pipeline.

Recent filings

Filing Released Lang Actions
SEC SCHEDULE 13G
Major Shareholding Notification
2020-04-09 English
SC 13G/A Filing
Major Shareholding Notification
2020-04-09 English
FORM 4 SUBMISSION
Director's Dealing
2020-03-10 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by GlycoMimetics, Inc. It registers additional shares of common stock to be issued under employee benefit plans such as the 2013 Equity Incentive Plan, Employee Stock Purchase Plan, and Inducement Plan. The document includes details about the registration fee, incorporation by reference of prior filings including the company's 10-K, and exhibits related to stock plans and legal opinions. Form S-8 is a registration statement used for securities to be offered to employees under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital market filing related to share issuance under employee plans. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2020-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 28, 2020. It includes a press release announcing financial results for the fourth quarter and year ended December 31, 2019, which is furnished as an exhibit. The document also discusses the adoption of an inducement stock plan by the Compensation Committee. The key financial information is presented as a press release rather than a full quarterly or annual report. The document is not a full Annual Report (10-K) or Interim Report (10-Q/IR), but rather a current report announcing financial results and other corporate events. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights. The document length (6922 characters) and content support this classification.
2020-02-28 English
10-K Filing
Annual Report FY 2019
2020-02-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.